ArticleJAMA network open2024
External Validation of the American Heart Association PREVENT Cardiovascular Disease Risk Equations.
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Pooled it
- Associations of the PREVENT Score with coronary artery and thoracic aortic calcification among South Asian Americans.American journal of preventive cardiology · 2026Article
- A next-generation prediction risk model for acute myocardial infarction: Derivation and validation in a multi-centre cohort.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Independent external validation and head-to-head comparison of guideline-recommended CVD risk prediction models.American journal of preventive cardiology · 2026Article
- External validation of American heart association predicting risk of cardiovascular disease EVENTs (PREVENT) equations in a Chinese population.Scientific reports · 2026Article
- Associations of the C-Reactive Protein-Albumin-Lymphocyte Index, Red Cell Distribution Width-Albumin Ratio, and Blood Urea Nitrogen-Albumin Ratio With All-Cause and Cardiovascular Mortality Among Adults With Preclinical Heart Failure.Clinical cardiology · 2026Article
- Epidemiology of cardiovascular-kidney-metabolic syndrome.Nature reviews. Nephrology · 2026Review
- Mapping and evaluation of global and country-specific cardiovascular disease risk prediction models.Future cardiology · 2026Review
- Associations of 10-year predicted ASCVD risk by the PREVENT equations with AI-analyzed coronary atherosclerotic plaque characteristics.American journal of preventive cardiology · 2026Article
- Performance of PREVENT Cardiovascular Risk in Electronic Health Record-Based Clinical Practice.JAMA network open · 2026Article
- Biomarkers for Screening and Diagnosis of Heart Failure in Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review.International journal of molecular sciences · 2026Review
- External validation of the PREVENT risk score: performance and clinical utility in an Iranian population.Scientific reports · 2026Article
- Prediction of cardiovascular disease risk in women and individuals with polycystic ovary syndrome using the American Heart Association PREVENT model: A long-term population-based cohort study.American journal of preventive cardiology · 2026Article
- Cardiovascular risk stratification without recalibration: A comparative study of the PREVENT and WHO risk scores in a multiethnic Brazilian cohort.American journal of preventive cardiology · 2026Article
- Interventional applications of a Stroke Heat Risk Prediction Model produce health benefits.Nature communications · 2026Article
- Model-Dependent Cardiovascular Risk Stratification in Obese Populations: Multicenter Study in Türkiye.International journal of general medicine · 2026Article
- Application of predicting risk of cardiovascular disease events equations on postoperative major adverse cardiac and cerebral events for patients undergoing thoracic surgery.Frontiers in cardiovascular medicine · 2026Article
- Thirty-Year Atherosclerotic Cardiovascular Disease Risk Among US Adults Aged 30 to 59 Years.Circulation. Population health and outcomes · 2026Article
- Development and validation of a prediction model for cardiovascular-kidney-metabolic syndrome progression: a multicenter study.Frontiers in nutrition · 2026Article
- Cardiovascular disease risk estimates using the new PREVENT Equation: The good, bad, and the ugly.American journal of preventive cardiology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The American Heart Association's Predicting Risk of Cardiovascular Disease Events (PREVENT) equations were developed to extend and improve on previous cardiovascular disease (CVD) risk assessments for the purpose of treatment initiation and patient-clinician communication. Objective: To assess prognostic capabilities, calibration, and discrimination of the PREVENT equations in a study sample representative of the noninstitutionalized, US general population. Design, Setting, and Participants: This prognostic study used data from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2010 data cycles. Participants included adults for whom 10-year follow-up data were available. Data curation and analyses took place from December 2023 through May 2024. Main Outcomes and Measures: Primary measures were risk estimated by the PREVENT equations, as well as risk estimates from the previous Pooled Cohort Equations (PCEs). The primary outcome was composite CVD-related mortality at 10 years of follow-up. Additional analyses compared the PREVENT equations against the PCEs. Model discrimination was assessed with receiver-operator characteristic curves and Harrell C statistic from proportional hazard regression; model calibration was determined as the slope of predicted versus observed risk. Results: The study cohort, accounting for NHANES complex survey design, consisted of 172.9 million participants (mean age, 45.0 years [95% CI, 44.6-45.4 years]; 52.1% women [95% CI, 51.5%-52.6%]). In analyses adjusted for the NHANES survey design, a 1% increase in PREVENT risk estimates was statistically significantly associated with increased CVD mortality risk (hazard ratio, 1.090; 95% CI, 1.087-1.094). PREVENT risk scores demonstrated excellent discrimination (C statistic, 0.890; 95% CI, 0.881-0.898) but moderate underfitting of the model (calibration slope, 1.13; 95% CI, 1.06-1.21). PREVENT risk models performed statistically significantly better than the PCEs, as assessed by the net reclassification index (0.093; 95% CI, 0.073-0.115). Conclusions and Relevance: In this prognostic study of the PREVENT equations, PREVENT risk estimates demonstrated excellent discrimination and only modest discrepancies in calibration. These findings provided evidence supporting utilization of the PREVENT equations for application in the intended population as suggested by the American Heart Association.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.